Short Communication

Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays

Dagmar Smitalova a,b, Dana Dvorakova c, Zdenek Racil d,e, Marianna Romzova a,1,*

a Department of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
b Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
c Centre of Molecular Biology and Gene Therapy, University Hospital Brno, Czech Republic
d Internal Haematology and Oncology Clinic, University Hospital Brno, Czech Republic
e Institute of Hematology and Blood Transfusion, Prague, Czech Republic

ARTICLE INFO

Keywords:
Chronic myeloid leukemia
BCR-ABL1 monitoring
GeneXpert BCR-ABL Monitor assay
RT-qPCR
Digital PCR

ABSTRACT

BCR-ABL1 molecular detection using quantitative PCR (qPCR) methods is the golden standard of chronic myeloid leukemia (CML) monitoring. However, due to variable sensitivity of qPCR assays across laboratories, alternative methods are tested. Digital PCR (dPCR) has been suggested as a robust and reproducible option. Here we present a comparison of droplet dPCR with routinely used reverse-transcription qPCR (RT-qPCR) and automated GeneXpert systems. Detection limit of dPCR was above 3 BCR-ABL1 copies, although due to background amplification the resulting sensitivity was 0.01% BCR-ABL1 (MR4.0). Nevertheless, in comparison with GeneXpert, dPCR categorized more than 50% of the patients into different MR groups, showing a potential for improved BCR-ABL1 detection.

1. Introduction

Specific targeting of the Bcr-Abl1 enzyme by tyrosine kinase inhibitors (TKI) revolutionized the management of chronic myeloid leukemia (CML) to the point that TKIs can offer near normal life expectancy for CML patients [1]. However, some CML patients do not achieve optimal response at defined treatment time points, and others even develop TKI resistance. Therefore, molecular monitoring is crucial for clinical management of CML [2]. Currently, quantitative reverse-transcription PCR (RT-qPCR) is the technique of choice used to assess BCR-ABL1 transcript levels in the clinics. However, it often shows insufficient sensitivity and inconsistent detection of minimal BCR-ABL1 levels [3]. Despite standardization of RT-qPCR results relative to an international scale (IS), issues with reproducibility across laboratories still persist [3,4].

Digital PCR (dPCR) offers high reproducibility, precision and increased sensitivity for rare target detection [5]. Recent studies
evaluating the suitability of dPCR as an alternative technique for BCR-ABL1 monitoring suggest that dPCR has increased sensitivity up to MR5.5, although higher false positivity rate (FPR) could lower the detection limit of this method [6–10]. Therefore, whether dPCR is indeed suitable for monitoring of CML patients remains unclear.

The objectives of our study were to evaluate the performance of droplet dPCR using the Europe Against Cancer (EAC) standardized BCR-ABL1 and ABL1 assays and to evaluate the suitability of dPCR for molecular monitoring of CML patients with low or undetectable levels of BCR-ABL1 in comparison with routinely used methods.

2. Materials and methods

2.1. Samples

A retrospective analysis was performed on 70 clinical samples from chronic phase CML patients and 15 samples from healthy volunteers used as BCR-ABL1 negative controls. All samples were obtained from the Department of Internal Medicine, Haematology and Oncology, University Hospital Brno. Characteristics of CML patients are listed in Supplementary Table 1. Informed consent was obtained from all enrolled subjects prior to participation in the study. The study protocol and subject sampling were reviewed and approved by an institutional ethical committee in agreement with the Declaration of Helsinki. Sample handling and storage is described in detail in Supplementary Data.

2.2. Calibrators

ERM AD623 BCR-ABL pDNA (Sigma-Aldrich) plasmid set [11] was used to assess the linearity of EAC assays by dPCR, according to the manufacturer’s recommendations. A Qiagen Ipsogen BCR-ABL1 Mbcr Fusion Gene Standard kit and an Ipsogen ABL Control Gene 3 Standard kit were used for quantification of BCR-ABL1 transcript by RT-qPCR in accordance with the manufacturer’s recommendations.

2.3. Quantitative PCR

All qPCR measurements were performed at the Centre of Molecular Biology and Gene Therapy, University Hospital Brno. Two methods, routinely performed to assess treatment response, were used: conventional RT-qPCR and the GeneXpert-based assay.

RT-qPCR quantification of BCR-ABL1 in K562 cells was performed on an Applied Biosystems 7300 Real-Time PCR System. Cepheid Xpert BCR-ABL Monitor test was used for quantification of BCR-ABL1 in clinical CML samples, according to the manufacturer’s recommendations. Reverse transcription and qPCR reaction conditions are described in detail in Supplementary Data and Table 1.

2.4. Digital PCR

All dPCR measurements were performed at the Central European Institute of Technology of Masaryk University Brno, Department of Molecular Medicine on Bio-Rad QX200 Droplet Digital PCR System (dPCR) according to the manufacturer’s recommendations. Reaction conditions are described in Supplementary Data and Table 1.

2.5. Statistical analysis

The formulae for calculation of FPR, limit of blank (LOB) and limit of detection (LOD) are concluded in Supplementary Data. Statistical analyses were generated using GraphPad Prism v.9 software. P values < 0.05 were considered significant.

Table 1
Summary of qPCR and dPCR workflow details.

|                          | Quantitative RT-PCR | Digital PCR        |
|--------------------------|----------------------|--------------------|
|                          | GeneXpert IV         | ABI 7300           | QX200               |
| RT                       | CML cartridge        | SSII+/VILO         | SSII+/VILO          |
| cDNA dilution            | CML cartridge        | 1.2+/2:1           | 1.2+/2:1            |
| RNA/PCR reaction         | 200 μL of blood      | ~200 ng+/−135 ng   | ~200 ng+/−135 ng    |
| Reaction/sample volume   | CML cartridge        | 40 μL/5μL          | 40 μL/5μL           |
| Pre-PCR processing       | No                   | No                 | Droplet generation  |
| Standard                 | No                   | Yes                | No                  |
| PCR type                 | Nested RT-PCR        | Real-Time PCR      | End point PCR       |
| Assay reaction           | Multiplex            | Singleplex         | Singleplex          |
| Results                  | Cq values            | Relative copy numbers | Absolute copy numbers |
| ΔΔCq                     |                      | Copies/sample      | Copies/sample       |
| Analysis                 | % ratio (IS)         | % ratio x CF (IS)  | % ratio             |

SSII - SuperScript II; VILO SuperScript VILO; Cq - cycle quantification; CF- conversion factor; IS - International scale; *conditions used for comparison of dPCR with RT-qPCR.
3. Results

3.1. Detection limit of dPCR using EAC assays

Evaluation of EAC assays’ linearity on dPCR showed near perfect correlation of expected and measured BCR-ABL1 and ABL1 copies across the dilution range of the ERM AD623 standard down to 10 copies, with $R^2_{\text{BCR-ABL1}} = 0.998$ and $R^2_{\text{ABL1}} = 0.999$, respectively (Supplementary Fig. 1).

Assessment of FPR was performed on a total number of 80 negative samples, including no template controls (NTC), and the samples from BCR-ABL1 negative controls. The FPR of NTC ($n = 28$) was 4% with LOB $= 1.4$ copies/sample, and the FPR of BCR-ABL1 negative controls ($n = 52$; 15 samples tested in 3 and more replicates) was 6% with LOB $= 3.2$ copies/sample (Supplementary Table 2). A

Fig. 1. Sensitivity and performance of BCR-ABL1 and ABL1 EAC assays measured by dPCR in comparison with quantitative PCR methods A. Sensitivity of EAC BCR-ABL1 assay measured by dPCR. BCR-ABL1 copy numbers measured in 3 independent dilution series prepared from a CML patient with 10% BCR-ABL1 IS. The line indicates the detection limit (0.01% BCR-ABL1 IS) after adjustment to LOD (3.3 copies/sample) calculated from the background amplification in BCR-ABL1 negative controls – NC. B. Comparison of BCR-ABL1 ratios (%) measured in K562 cell line dilution series using RT-qPCR (black circles) and dPCR (white triangles). Asterisks indicate the significance level determined by Mann-Whitney test: ***$P < 0.0001$; **$P < 0.001$, *$P < 0.05$. C. Correlation of BCR-ABL1 ratios % measured by GeneXpert and dPCR in 36 clinical samples (MR3.0-MR4.5). Pearson correlation analysis was used to determine $R^2 = 0.4925$ with 95% CI= 0.4851 to 0.8373. D. 3-way comparison of BCR-ABL1 ratios (%) measured by RT-qPCR (black circles), GeneXpert (black diamond) and dPCR (white triangles) in 12 samples from CML patients in MR3.0-MR4.5. The significance between the methods was determined by Wilcoxon test: RT-qPCR vs. GeneXpert $P^{**} = 0.0049$; dPCR vs GeneXpert $P^{***} = 0.0010$. A
3.2. Comparison of RT-qPCR and dPCR quantification

For comparison of quantitative and digital PCR, we used K562 cell line dilution series, corresponding to 10%, 1%, 0.1%, 0.01%, and 0.0032% BCR-ABL1\(^{15}\). Despite overall correlation of ratios (Supplementary Fig. 2), we observed significant differences in copy numbers quantification between RT-qPCR and dPCR. In detail, in the samples containing high transcript levels (10%-0.1% BCR-ABL1\(^{15}\), RT-qPCR detected significantly more BCR-ABL1 copies than dPCR (P < 0.0001). Conversely, in the sample with low transcript levels (0.0032% BCR-ABL1\(^{15}\)), RT-qPCR quantified significantly less BCR-ABL1 copies compared to dPCR (P = 0.0477). Moreover, in all sample categories dPCR detected significantly less ABL1 copies (P < 0.0001) (Supplementary Fig. 3; Supplementary Table 4). As a result, BCR-ABL1\(^{15}\) ratios assessed by RT-qPCR were underestimated, even after correction to IS, compared to dPCR ratios (Fig. 1B; Supplementary Table 5).

The discrepancy of copy numbers was also observed in samples from patients in major and deep molecular response (≤MR3) (n = 12). RT-qPCR still quantified significantly more ABL1 copies than dPCR in these samples (median copies of 133,971 by RT-qPCR vs. 73,333 by dPCR) (Supplementary Table 6, Supplementary Fig. 4). The BCR-ABL1 copy numbers showed similar trend.

3.3. BCR-ABL1 monitoring in clinical CML samples

A total of 44 CML patients, routinely monitored by GeneXpert, were tested by dPCR. Patient samples were categorized according to the BCR-ABL1\(^{15}\) transcript level as follows: ≤10% (n = 3), ≤1% (n = 3), ≤0.1% (n = 14), ≤0.01% (n = 11) and ≤0.0032% (n = 13). We observed significant differences in the ratios measured by dPCR and GeneXpert in the patients with low transcript levels (n = 36; ≤0.1% BCR-ABL1\(^{15}\)) (Supplemental Figs. 5 and 6), which also resulted in low correlation between the methods (R\(^2\)=0.49; Fig. 1C). Overall, 56% (25/44) of CML patients were placed into different MR categories by dPCR.

In addition, in 12/44 patients (≤0.1% BCR-ABL1\(^{15}\)) 3-way comparison of BCR-ABL1 ratios was performed as shown in Fig. 1D. Both ratios generated by RT-qPCR and dPCR were significantly different from GeneXpert ratios (PRT-qPCR = 0.0049; PDPCR = 0.0010).

Finally, in 40% (10/25) of CML patients, evaluated by GeneXpert as BCR-ABL1 negative, dPCR was able to detect BCR-ABL1 transcript (Supplementary Table 7). However, only 8% of these patients (2/25) were evaluated as positive, with BCR-ABL1 concentration above LOD (3.3 BCR-ABL1 copies).

4. Discussion

The sensitivity of dPCR for BCR-ABL1 quantification has already been demonstrated, showing its superiority compared to RT-qPCR (LOD up to MR5.5) [12]. In our study, we showed that dPCR can attain sensitivity above MR5.0. However, we also observed a false positive amplification in BCR-ABL1 negative controls, not distinguishable from the lowest copy numbers in positive samples. Therefore, final sensitivity was decreased to MR4.0.

The assessment of the false positivity and the detection limit is especially important for the assays, monitoring minimal residual disease. The EAC assays for BCR-ABL1 detection have been validated on dPCR in the studies of Franke and Maier [9,10], revealing up to 5% false positivity. In our study, we observed a fairly high FPR of 6%. Alikian [7] described similarly increased false positivity in a study comparing three dPCR platforms, using the same combination of an EAC qPCR assays in multiplex, suggesting that this combination and cDNA synthesis was performed using the same RT enzyme, we hypothesized that differences among the two methods are likely caused by quantification principles (plasmid standard versus absolute quantification). In addition, dPCR outperformed RT-qPCR in quantifying the lowest transcript levels, which are most likely at the lower detection limit of RT-qPCR. We observed analogous observations when comparing dPCR with GeneXpert. In clinical samples with ≤0.1 BCR-ABL1\(^{15}\)% and BCR-ABL1 negative samples dPCR yielded more sensitive measurements, GeneXpert assay used for this comparison was validated to MR4.0 [16], which might influence the discrepancy at the lowest transcript levels (<0.01% BCR-ABL1\(^{15}\)). Still, more than half of the patients in MR3.0 - MR4.0 were categorized into different MR classes by dPCR. Similarly, Folta reported consistent MR levels only in 29/50 samples in a comparison of dPCR with more sensitive GeneXpert Ultra kit with sensitivity of MR4.5. [15]

Our study demonstrated that dPCR, tested with standard EAC assays, provided a detection limit of above 3 BCR-ABL1 copies/sample, which corresponded to sensitivity of conventional quantitative methods. Nevertheless, dPCR categorized more than 50% of the CML patients into different MR categories compared to quantitative GeneXpert. CML patients in deep molecular response considered for
TKI cessation could benefit from more sensitive monitoring using well optimized dPCR assays, however an international standardization independent from RT-qPCR would be required to promote dPCR as an alternative method.

CRediT authorship contribution statement

Dagmar Smitalova: Investigation, Writing – original draft, preparation. Dana Dvorakova: Resources, Conceptualization. Zdenek Racil: Resources, Writing – review & editing. Marianna Romzova: Conceptualization, Methodology, Supervision.

Declaration of competing interest

Authors DS, DD, ZR, and MR have no competing interests.

Acknowledgements

We would like to thank Veronika Mancikova for her valuable assistance with final editing and proofreading. We would also like to acknowledge Michaela Zejdova for her assistance with experimental work on sensitivity testing.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.plabm.2021.e00210.

Funding

This work was supported by the Ministry of Health of the Czech Republic Grants [NR.17-30397A, FNBr.65269705] and Ministry of Education, Youth and Sports of the Czech Republic Specific University Research Grant [MUNI/A/1105/2018] and [MUNI/A/1395/2019].

References

[1] K. Sasaki, S.S. Strom, S. O’Brien, E. Jabbour, F. Ravandi, M. Konopleva, G. Borthakur, N. Pennmaraju, N. Daver, P. Jain, S. Pierce, H. Kantarjian, J.E. Cortes, Detection and quantitation of BCR-ABL1 fusion transcripts by droplet digital PCR versus real-time PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia, Blood 116 (2010) 5775–5781, https://doi.org/10.1182/blood-2010-06-291641.

[2] N.C.P. Cross, H.E. White, M.C. Müller, G. Saglio, A. Hochhaus, Standardized definitions of molecular response in chronic myeloid leukemia, Leukemia 26 (2012) 2172–2175, https://doi.org/10.1038/leu.2012.104.

[3] T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N.C.P. Cross, B.J. Drucker, J. Gabert, D. Grimwade, R. Hehlmann, S. Kamel-Reid, J.H. Lipton, J. Longtime, G. Martinelli, G. Saglio, S. Soverini, W. Stock, J.M. Goldman, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood 108 (2006) 28–37, https://doi.org/10.1182/blood-2006-01-0092.

[4] C.M. Hindson, J.R. Chevillet, E.A. Briggs, E.G. Albano, H.A. Briggs, E.N. Gallichotte, A. Hochhaus, C.T. Dietz, M.C. Müller, D. Niederwieser, T. Lange, Quantitation of BCR-ABL mRNA establishment of the world Health organization international genetic reference panel for quantitation of BCR-ABL mRNA, Blood 116 (2012) 251, https://doi.org/10.1182/blood-2010-06-291541.

[5] J.E. Marum, S. Branford, Current developments in molecular monitoring in chronic myeloid leukemia, Ther. Adv. Hematol. 7 (2016) 237–251, https://doi.org/10.1177/2040620716657994.

[6] N.C.P. Cross, H.E. White, T. Ernst, L. Weiden, C. Dietz, G. Saglio, F.X. Mahon, C.C. Wong, D. Zheng, S.W. Wang, S. Akiki, F. Albano, H. Andrikovics, J. Anwar, G. Balschewski, J. Benetl, J. Beveridge, N. Boeckx, N. Cerveira, S.M. Cheng, D. Colomer, S. Cuarda, F. Daraio, D. Dulacq, L. Eggen, H. El Houssni, G. Gerrard, M. Gniot, B. Izzo, D. Jacquin, T.J.W.M. Janssen, S. Jeromin, T. Jurcek, D.W. Kim, K. Machova-Polakova, J. Martinez-Lopez, M. McBean, S. Mesanovic, G. Mitterbauer-Hohendanner, H. Mobtaker, M.J. Mozzi, V. Nayci, N. Palliaga, P. Panagiotidou, R.D. Press, Y.Z. Qin, J. Richter, A. Hochhaus, F.X. Mahon, The concept of treatment-free remission in chronic myeloid leukemia, Leukemia 30 (2016) 1638–1647, https://doi.org/10.1038/leu.2016.115.

[7] G.-N. Franke, J. Maier, K. Wildenberger, M. Cross, M. Shelton, A. Hochhaus, Standardized definitions of molecular response in chronic myeloid leukemia, Leukemia 26 (2012) 2172–2175, https://doi.org/10.1038/leu.2012.104.

[8] G.-N. Franke, J. Maier, K. Wildenberger, M. Cross, O. Frank, F. Giles, A. Hochhaus, C.T. Dietz, M.C. Müller, D. Niederwieser, T. Lange, Quantification of BCR-ABL with digital PCR results in a significantly lower rate of deep molecular responses when compared to RT-qPCR in CML patients treated in the ENEST1st trial, Blood 126 (2015), https://doi.org/10.1182/blood-2015-04-651129.

[9] M.C. Hindson, J.R. Chevillet, E.A. Briggs, E.G. Albano, H.A. Briggs, E.N. Gallichotte, A. Hochhaus, C.T. Dietz, M.C. Müller, D. Niederwieser, T. Lange, Absolute quantification by droplet digital PCR versus analog real-time PCR, Nat. Methods 10 (2013) 1003–1005, https://doi.org/10.1038/nmeth.2633.

[10] G.-N. Franke, J. Maier, M. Cross, O. Frank, F. Giles, A. Hochhaus, C.T. Dietz, M.C. Müller, D. Niederwieser, T. Lange, Quantification of BCR-ABL1 fusion transcripts by droplet digital PCR, J. Mol. Diagn. 16 (2014) 174–179, https://doi.org/10.1016/j.jmoldx.2013.10.007.

[11] M. Alikian, A.S. Whale, S. Akiki, K. Piechocki, C. Torrado, T. Myint, S. Cowen, M. Griffiths, A.G. Reid, J. Apperley, H. White, J.F. Huggett, L. Foroni, RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia, Clin. Chem. 63 (2017) 525–531, https://doi.org/10.1373/clinchem.2016.263824.

[12] S. Saulele, J. Richter, A. Hochhaus, F.X. Mahon, Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR, Leukemia 30 (2016) 1602–1603, https://doi.org/10.1177/2040620716657994.

[13] H. Goh, H. El Housni, D. Jones, V. Kairisto, S. Kamel-reid, T. Kim, Establishment of the world Health organization international genetic reference panel for quantitation of BCR-ABL mRNA establishment of the first world Health organization international genetic reference panel for quantitation of BCR-ABL mRNA, Blood 116 (2012) 118, https://doi.org/10.1182/blood-2010-06-291541.
[14] R.F. Andersen, N. Palligaard, Exceeding MR5.0 sensitivity in routine BCR-ABL1 analysis using multiplex digital PCR, Blood 124 (2014), https://doi.org/10.1182/blood.V124.21.4540.4540, 4540–4540.

[15] A. Folta, T. Jurcek, B. Kubesova, D. Zackova, J. Mayer, I. Jeziskova, A comparison of two standardized quantitative RT-PCRs with CE IVD kit for digital PCR in CML patients with different level of BCR-ABL1 transcripts, Blood 134 (2019) 1646, https://doi.org/10.1182/blood-2019-125551.

[16] A. Enjeti, N. Granter, A. Ashraf, L. Fletcher, S. Branford, P. Rowlings, S. Dooley, A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system, Pathology 47 (2015) 570-574, https://doi.org/10.1097/PAT.0000000000000293.